证券代码：603233 证券简称：大参林 公告编号：2025-057 大参林医药集团股份有限公司 (一) 股东大会召开的时间：2025 年 9 月 15 日 (二) 股东大会召开的地点：广州市荔湾区龙溪大道 410 号大参林集团综合楼 4 楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 二、 议案审议情况 审议结果：通过 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 306 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 862,237,161 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 75.1609 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，经过半数董事推举，由董事柯国强主持本次股 东大会 ...

Core Viewpoint - The article discusses the sudden decline of the pharmacy industry in China, highlighting the rapid closure of stores and the challenges faced by pharmacy owners and employees due to various market and regulatory changes [7][13][31]. Group 1: Industry Overview - In the past year, approximately 39,000 pharmacies closed nationwide, with a closure rate of 5.7%, and predictions suggest an additional 60,000 to 100,000 closures this year [13]. - The pharmacy industry, once considered a "golden track" for investment, has seen major players like Guoda Pharmacy and Shandong's Shuyupingmin Pharmacy struggling, with significant store closures and stock sell-offs by shareholders [16][31]. Group 2: Factors Contributing to Decline - The decline is attributed to three main factors: competition from community hospitals, the rise of online pharmacies, and tightening regulations on medical insurance reimbursements [34][41][49]. - Community hospitals have become popular among younger consumers, leading to a loss of clientele for pharmacies, particularly in the chronic disease segment [36][40]. - Online platforms have disrupted traditional pharmacy sales, offering lower prices and convenience, which has eroded the competitive edge of brick-and-mortar pharmacies [42][46]. Group 3: Financial Impact - Many listed pharmacy chains are experiencing significant profit declines, with net profit reductions starting at 60%, and some companies like Shuyupingmin facing potential losses of up to 220 million yuan [31][50]. - The shift in the market has forced many pharmacy owners to seek alternative employment, with some transitioning to factory work or food delivery services [22][23]. Group 4: Adaptation Strategies - Pharmacies are attempting to adapt by diversifying their offerings, such as incorporating health seminars and free health check-ups to build community ties and enhance customer loyalty [58][67]. - The future of the pharmacy industry is expected to focus on professional services and operational efficiency rather than mere expansion, with some pharmacies exploring AI-assisted consultations to improve service delivery [70].

Core Viewpoint - The "National Drug Safety Publicity Week" in China, held from September 1 to September 7, 2025, focuses on the theme "Drug Safety, Regulation for the People," with various activities organized by market supervision departments in Zhanjiang City to enhance public awareness and understanding of drug safety and regulations [1][2][3]. Group 1: Activities and Engagement - Various forms of public engagement were utilized, including science popularization, public open days, and free health services such as blood pressure testing and herbal tea distribution [2][4]. - The activities featured interactive elements like Q&A sessions, distribution of educational materials, and demonstrations of common drug safety practices [5][6]. - A total of 250 promotional materials related to drugs, medical devices, and cosmetics were distributed, along with over 900 educational handouts on safe medication practices [2][3]. Group 2: Educational Focus - The events emphasized the importance of understanding drug safety laws, including the "Drug Safety Law of the People's Republic of China" and regulations on medical devices and cosmetics [2][3]. - Educational materials included handbooks on safe medication, adverse drug reactions, and how to identify false drug advertisements, aimed at increasing public awareness and knowledge [5][6]. - Specific attention was given to children's medication safety and the dangers of drug abuse, with tailored materials and guidance provided to families [6][7]. Group 3: Community Involvement - The activities encouraged community participation, with local pharmacies and health professionals actively involved in providing consultations and health services [4][6]. - The market supervision departments collaborated with local businesses to enhance the reach of the drug safety message, utilizing electronic displays and community events to promote awareness [7][8]. - Overall, the initiative aimed to foster a supportive environment for drug safety, encouraging public engagement and legal awareness among both consumers and drug producers [4][8].

Core Viewpoint - Dazhonglin's stock price has shown fluctuations, with a recent decline of 2.02%, while the company has experienced a year-to-date increase of 14.92% in stock price [1] Group 1: Stock Performance - As of September 11, Dazhonglin's stock price is reported at 16.95 yuan per share, with a market capitalization of 19.303 billion yuan [1] - The stock has seen a net outflow of 8.4672 million yuan in principal funds, with significant selling pressure observed [1] - Over the past five trading days, the stock has decreased by 0.88%, while it has increased by 0.41% over the last 20 days and 8.79% over the last 60 days [1] Group 2: Financial Performance - For the first half of 2025, Dazhonglin achieved a revenue of 13.523 billion yuan, reflecting a year-on-year growth of 1.33%, and a net profit attributable to shareholders of 798 million yuan, which is a 21.38% increase [2] - Cumulatively, Dazhonglin has distributed 3.355 billion yuan in dividends since its A-share listing, with 1.624 billion yuan distributed over the past three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of Dazhonglin shareholders is reported at 31,500, a decrease of 10.07% from the previous period [2] - The average number of circulating shares per shareholder has increased by 11.20% to 36,097 shares [2] - Hong Kong Central Clearing Limited is the fourth largest circulating shareholder, holding 90.4479 million shares, an increase of 12.4318 million shares from the previous period [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●减持计划实施前股东持股的基本情况 本次减持计划实施前，大参林（维权）医药集团股份有限公司（以下简称"公司"）控股股东及其一致行 动人合计持有公司股份729,368,982股，占公司总股本的64.04%，其中，柯金龙持有公司股份 229,631,849股，占公司总股本比例为20.16%。 ●减持计划的实施结果情况 2025年6月5日，公司在上海证券交易所披露了《持股5%以上股东减持股份计划公告》（公告编号： 2025-036），为调整资产和融资结构，偿还个人债务，降低股票质押率，股东柯金龙拟通过大宗交易减 持其持有的公司股份不超过22,776,957股，即不超过公司总股本的2%。 截至2025年9月9日，柯金龙已通过大宗交易方式减持22,700,000股，占公司总股本的1.99%。截至本公 告披露日，上述减持计划已实施完毕。 本次减持计划完成后，控股股东及一致行动人合计持有公司股份由729,368,982 ...

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Dacianlin Pharmaceutical Group Co., Ltd., which has resulted in a decrease in the shareholding percentage of the controlling shareholder and its concerted parties. Group 1: Shareholding Before Reduction - Before the implementation of the reduction plan, the controlling shareholder and its concerted parties held a total of 729,368,982 shares, accounting for 64.04% of the total share capital of the company, with Ke Jinlong holding 229,631,849 shares, representing 20.16% of the total share capital [2]. Group 2: Implementation of Reduction Plan - On June 5, 2025, the company disclosed a share reduction plan, where Ke Jinlong intended to reduce his holdings by up to 22,776,957 shares, or 2% of the total share capital, through block trading to adjust asset and financing structures, repay personal debts, and lower stock pledge rates [3]. - As of September 9, 2025, Ke Jinlong successfully reduced his holdings by 22,700,000 shares, which is 1.99% of the total share capital. Following this reduction, the total shares held by the controlling shareholder and concerted parties decreased to 706,668,982 shares, resulting in a new holding percentage of 62.05% [3][4]. Group 3: Post-Reduction Shareholding and Compliance - The completion of the reduction plan does not trigger a mandatory tender offer and does not lead to any changes in the controlling shareholder or actual controller of the company. The company will continue to ensure compliance with relevant disclosure obligations by the information disclosure obligors [5].

证券代码：603233 证券简称：大参林 公告编号：2025-056 大参林医药集团股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度暨减持计划实施 完毕的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 减持计划实施前股东持股的基本情况 本次减持计划实施前，大参林医药集团股份有限公司（以下简称"公 司"）控股股东及其一致行动人合计持有公司股份 729,368,982 股，占公司 总股本的 64.04%，其中，柯金龙持有公司股份 229,631,849 股，占公司总 股本比例为 20.16%。 减持计划的实施结果情况 2025 年 6 月 5 日，公司在上海证券交易所披露了《持股 5%以上股东减 持股份计划公告》（公告编号：2025-036），为调整资产和融资结构，偿还 个人债务，降低股票质押率，股东柯金龙拟通过大宗交易减持其持有的公 司股份不超过 22,776,957 股，即不超过公司总股本的 2%。 截至 2025 年 9 月 9 日，柯金龙已通过大宗交易方式减持 22,700,000 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

证券时报·数据宝统计显示，大参林今日收盘价为17.72元，上涨0.11%，日换手率为0.69%，成交额为 1.38亿元，全天主力资金净流出634.89万元，近5日该股累计上涨2.78%，近5日资金合计净流出1765.75 万元。 大参林9月9日大宗交易平台共发生8笔成交，合计成交量2270.00万股，成交金额3.74亿元。成交价格均 为16.48元，相对今日收盘价折价7.00%。从参与大宗交易营业部来看，机构专用席位共出现在8笔成交 的买方或卖方营业部中，合计成交金额为3.74亿元，净买入3.74亿元。 两融数据显示，该股最新融资余额为2.25亿元，近5日减少1025.80万元，降幅为4.36%。 机构评级来看，近5日共有4家机构给予该股评级，预计目标价最高的是东方证券，9月8日东方证券发布 的研报预计公司目标价为20.16元。（数据宝） 9月9日大参林大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | 业部 | | | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 9月9日，大参林（维权）收涨0.11%，收盘价为17.72元，发生8笔大宗交易，合计成交量2270万股，成 交金额3.74亿元。 第1笔成交价格为16.48元，成交600.00万股，成交金额9,888.00万元，溢价率为-7.00%，买方营业部为机 构专用，卖方营业部为中信证券股份有限公司深圳深南中路中信大厦证券营业部。 第2笔成交价格为16.48元，成交454.00万股，成交金额7,481.92万元，溢价率为-7.00%，买方营业部为机 构专用，卖方营业部为中信证券股份有限公司深圳深南中路中信大厦证券营业部。 第5笔成交价格为16.48元，成交300.00万股，成交金额4,944.00万元，溢价率为-7.00%，买方营业部为机 构专用，卖方营业部为中信证券股份有限公司深圳深南中路中信大厦证券营业部。 第6笔成交价格为16.48元，成交243.00万股，成交金额4,004.64万元，溢价率为-7.00%，买方营业部为机 构专用，卖方营业部为中信证券股份有限公司深圳深南中路中信大厦证券营业部。 第7笔成交价格为16.48元，成交22.00 ...